The prognostic role of HBV infection in chronic lymphocytic leukemia
- PMID: 29761374
- PMCID: PMC11813474
- DOI: 10.1007/s00432-018-2663-z
The prognostic role of HBV infection in chronic lymphocytic leukemia
Abstract
Purpose: We attempt to assess the impact of hepatis-B virus (HBV) status on the prognosis of chronic lymphocytic leukemia (CLL) using a Chinese case cohort.
Methods: Five hundred and one consecutive newly diagnosed subjects with CLL were enrolled in this case cohort. HBV infection was defined as hepatitis B surface antigen (HBsAg) positive or hepatitis-B core antibody (HBcAb) positive. Univariate and stepwise multivariate Cox regression analyses were used to screen the prognostic risk factors associated with the end point of time-to-treatment (TTT) or overall survival (OS). Bootstrap re-sampling method was used to evaluate the model's internal validity. The discriminative ability of the models was evaluated using time-dependent receiver-operator characteristic (ROC) curves and corresponding areas under the curve (AUC).
Results: One hundred and twenty-one subjects (24%) among 501 patients were HBV positive. HBV infection was an independent predictor for the prognosis of TTT (HR = 1.37; 95% CI 1.04-1.80) or OS (HR =2.85; 95% CI 1.80-4.52). The AUCs for HBV infection were 0.62 (95% CI 0.58-0.66) for TTT and 0.69 (95% CI 0.66-0.72) for OS, respectively. When we combined HBV infection with the traditional clinical and biological factors, significant improvements for model's discrimination were observed for TTT [AUC: 0.81 (95% CI: 0.77-0.85) vs. 0.78 (95% CI: 0.74-0.82), P < 0.001] and OS [AUC: 0.81 (95% CI 0.76-0.86) vs. 0.76 (95% CI 0.71-0.82), P < 0.001). Further bootstrap re-sampling method revealed good internal consistence for the final optimal models (Average AUC: 0.78 for TTT and 0.79 for OS based on 1000 bootstraps).
Conclusions: Our results indicated that HBV infection should be served as an important risk predictor for prognosis of CLL (TTT and OS).
Keywords: Chronic lymphocytic leukemia; HBV; Overall survival; Prognostic biomarker; Time to first treatment.
Conflict of interest statement
These authors have no conflicts of interest.
Figures
References
-
- Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206 - PubMed
-
- Chen MH, Hsiao LT, Chiou TJ et al (2008) High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s Lymphoma. Ann Hematol 87:475–480 - PubMed
-
- Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990–4997 - PubMed
-
- Cortese D, Sutton LA, Cahill N et al (2014) On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia 28:710–713 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
